What is Bot Image?
Bot Image, Inc. operates at the vanguard of medical technology, specifically targeting the high-stakes field of prostate cancer screening. Its flagship innovation, ProstatID, represents a milestone in the industry as the first FDA-cleared AI software for prostate cancer detection in North America. The company provides a comprehensive suite of diagnostic tools designed for urologists and imaging centers, effectively bridging the gap between complex MRI data and actionable clinical insights. Through its MaleScan service, Bot Image facilitates rapid, AI-supported diagnostic reporting, which significantly enhances the efficiency of patient care pathways and diagnostic precision in a clinical setting.
How much funding has Bot Image raised?
Bot Image has raised a total of $1.5M across 3 funding rounds:
Multiple Rounds
$1.5M
Stock/Share Issuance (2025): $200K, investors not publicly disclosed
Stock/Share Issuance (2025): $1M, investors not publicly disclosed
Stock/Share Issuance (2025): $280K, investors not publicly disclosed
Key Investors in Bot Image
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Bot Image?
With this major enterprise-level funding, Bot Image is poised to accelerate its commercial expansion and deepen its research and development capabilities. The strategic allocation of this capital will likely focus on scaling the adoption of ProstatID across broader healthcare networks and potentially expanding its diagnostic algorithms to address other oncology-related imaging challenges. As the company transitions into this next phase of growth, the focus will remain on maintaining its regulatory leadership while optimizing the integration of its software into existing hospital workflows. The firm is well-positioned to capitalize on the increasing demand for automated, high-accuracy diagnostic solutions in the global oncology market.
See full Bot Image company page
